Overview

Levosimendan Pretreatment for Weaning Patients From Cardio-Pulmonary Bypass

Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
The study evaluates the efficacy of intravenous levosimendan treatment started during a coronary artery bypass operation to wean patients from a heart lung machine.
Phase:
Phase 2
Details
Lead Sponsor:
Orion Corporation, Orion Pharma
Treatments:
Simendan